Abstract
Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have